Immunovant (NASDAQ: IMVT)
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.380 | -0.410 | -0.0300 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Immunovant (NASDAQ: IMVT) through any online brokerage.
Other companies in Immunovant’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Kezar Life Sciences (NASDAQ:KZR), Centessa Pharmaceuticals (NASDAQ:CNTA), Altimmune (NASDAQ:ALT) and Inovio Pharmaceuticals (NASDAQ:INO).
The latest price target for Immunovant (NASDAQ: IMVT) was reported by Wells Fargo on Wednesday, December 8, 2021. The analyst firm set a price target for 9.00 expecting IMVT to rise to within 12 months (a possible 129.59% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Immunovant (NASDAQ: IMVT) is $3.92 last updated Today at June 30, 2022, 3:33 PM UTC.
There are no upcoming dividends for Immunovant.
Immunovant’s Q1 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Immunovant.
Immunovant is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.